The Column Group Building Bio Giants With $259M Venture Fund
San Francisco Business Times -- Rick Klausner is looking for the next Genentech.
The former head of the National Cancer Institutes -- along with a top-tier team of partners and science advisers, including three Nobel laureates -- is unleashing a $259 million venture capital fund for startup biotechs attacking broad medical problems.
The former head of the National Cancer Institutes -- along with a top-tier team of partners and science advisers, including three Nobel laureates -- is unleashing a $259 million venture capital fund for startup biotechs attacking broad medical problems.